Metformin
An antidiabetic.
General information
Metformin is a biguanide antidiabetic. It has antihyperglycemic properties and reduces LDL cholesterol and triglyceride levels (NCIt).
The TOGETHER trial data show that metformin does not reduce the rate of COVID-19-related hospitalization among high-risk patients. No other clinical benefit was observed either (Reis et al., 2022).
Metformin on PubChem
Metformin on DrugBank
Metformin on Wikipedia
Marketed as
ACTOPLUS MET; AVANDAMET; FORTAMET; GLUBRAVA; GLUCOPHAGE; GLUCOVANCE; GLUMETZA; GLYCON; INVOKAMET; JANUMET; JENTADUETO; KAZANO; KOMBIGLYZE; KOMBOGLYZE; QTERNMET; RIOMET; SEGLUROMET; SYNJARDY; TRIJARDY; VELMETIA; XIGDUO

CN(C)C(=N)N=C(N)N
Supporting references
Link | Tested on | Impact factor | Notes | Publication date | DB entry date |
---|---|---|---|---|---|
Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19
Preprint |
Patients | significantly associated with reduced mortality in women with obesity or type 2 diabetes hospitalized with COVID-19 |
Jun/20/2020 | Jun/23/2020 | |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule |
in silico | 42.78 | Apr/30/2020 | Mar/30/2020 |
Clinical trials
ID | Title | Status | Phase | Start date | Completion date |
---|---|---|---|---|---|
NCT04604678 | Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 | Not yet recruiting | Phase 2 | Feb/01/2021 | Oct/01/2021 |
NCT04626089 | Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2 | Withdrawn | Phase 2 | Feb/01/2021 | Feb/01/2021 |
NCT04510194 | COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) | Active, not recruiting | Phase 3 | Jan/01/2021 | Feb/01/2023 |
NCT04625985 | Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. | Completed | Phase 2 | Jul/14/2020 | Mar/18/2021 |